Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table reconciles reported revenues to net loss under the significant expense principle for the three months ended March 31, 2025 and 2024:

	Three Months Ended March 31,
	2025		2024
Revenues	$	8,720	$	12,053
Costs and expenses:
Total Manufacture and Supply Expenses	3,652		4,389
R&D Project expenses:
Anaphylm project expenses	2,488		3,147
AQST-108 project expenses	195		789
Libervant project expenses	—		17
R&D other expenses:
Personnel costs1	2,132		1,704
Other2	546		275
Total Research and Development Expenses	5,361		5,932
Selling expenses:
Personnel costs3	694		932
Other4	2,262		140
Total Selling expenses	2,956		1,072
General & Administrative expenses:
Personnel costs5	4,840		4,661
Other6	11,276		4,956
Total General and Administrative Expenses	16,116		9,617
Total Selling, General and Administrative Expenses	19,072		10,689
Total costs and expenses	28,085		21,010
Loss from operations	(19,365)		(8,957)
Other expenses	(3,565)		(3,871)
Net loss before income taxes	(22,930)		(12,828)
Net loss	$	(22,930)	$	(12,828)
Comprehensive loss	$	(22,930)	$	(12,828)

1 - R&D Personnel costs include payroll expenses, share-based compensation expenses and severance

2 - Other Research and Development expenses include preclinical, consulting, maintenance, and testing fees

3 - Selling Personnel costs include payroll expenses and severance

4 - Other Selling expenses include commercialization and other related expenses

5 - G&A Personnel costs include payroll expenses, share-based compensation expenses and severance

6 - Other General and Administrative expenses include legal/patent fees, insurance fees, IT expenses, investor relations expenses, regulatory fees, facility and other costs